Navigating the Cost of Care: India Intensifies Oversight of Medical Device Pricing and Trade Margins

Published: March 18, 2026

NEW DELHI — In a move to protect patient pockets while balancing market dynamics, the Indian government has reaffirmed its commitment to regulating the cost of essential medical devices. On Tuesday, the Ministry of Chemicals and Fertilizers clarified the robust mechanisms currently in place to curb “trade margins”—the difference between the price at which a manufacturer sells a device and the final price paid by the patient—which have historically driven up healthcare costs. While the government confirmed there is currently no proposal for a unified “One Nation, One Price” framework, the National Pharmaceutical Pricing Authority (NPPA) continues to enforce strict ceiling prices on life-saving equipment, ranging from coronary stents to orthopedic implants.

The Architecture of Affordability

For years, the high cost of medical interventions has been a primary driver of medical indebtedness in India. At the heart of the government’s strategy to combat this is the Drugs (Prices Control) Order (DPCO), 2013. Under this mandate, the NPPA fixes “ceiling prices” for devices listed in the National List of Essential Medicines (NLEM).

According to recent data released by the Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, the price caps on coronary stents remain a cornerstone of this policy. Currently, the ceiling price for a Bare Metal Stent (BMS) is fixed at ₹10,692.69, while the more advanced Drug Eluting Stents (DES) are capped at ₹38,933.14.

“Price regulation in the medical device sector is not just about economics; it’s about equity,” says Dr. Aradhana Singh, a health policy analyst not involved in the government report. “Before these caps, patients were often charged markups of 300% to 400% on stents. Fixing a ceiling price ensures that a life-saving procedure doesn’t become a luxury reserved for the wealthy.”

Beyond Stents: Expanding the Safety Net

The regulatory umbrella extends far beyond cardiac care. The NPPA has utilized “public interest” clauses to intervene in other high-stakes surgical areas:

• Orthopedic Implants: Ceiling prices for knee replacement systems, first notified in 2017, have now been extended until November 15, 2026.

• Home Healthcare Tools: In a legacy move following the COVID-19 pandemic, the “Trade Margin Rationalization” (TMR) approach continues to apply to everyday essentials like Pulse Oximeters, Blood Pressure Monitors, Nebulizers, Digital Thermometers, and Glucometers.

For devices not specifically listed as “scheduled” (those without a fixed ceiling price), the law prevents manufacturers from increasing the Maximum Retail Price (MRP) by more than 10% within any 12-month period.

Transparency at the Hospital Bedside

One of the most significant shifts for consumers is the requirement for transparency in billing. It is no longer enough for a hospital to provide a lump-sum bill for a procedure like an angioplasty.

Under NPPA notifications, hospitals and clinics must specifically itemize the cost of the stent in the final invoice. This must include:

1. The category (BMS vs. DES)

2. The brand name and manufacturer

3. The batch number and technical specifications

This level of detail allows patients to verify that they are being charged according to the government-mandated rates and provides a trail for regulators to track overcharging.

The Debate Over “One Nation, One Price”

While the current system monitors and caps prices, some advocacy groups have called for a more uniform “One Nation, One Price” framework to eliminate regional variations in hospital handling charges. However, the Department of Pharmaceuticals confirmed yesterday that no such proposal is currently under consideration.

Industry experts suggest that a “one size fits all” price might be difficult to implement due to the varying overhead costs of healthcare facilities. “A small nursing home and a multi-specialty quaternary care hospital have different operating costs,” explains Rajiv Nath, Forum Coordinator for the Association of Indian Medical Device Industry (AiMeD). “The challenge is finding the ‘Goldilocks zone’—prices that are affordable for patients but high enough to encourage innovation and quality manufacturing.”

Limitations and Consumer Vigilance

Despite these regulations, challenges remain. The NPPA relies heavily on a network of Price Monitoring and Resource Units (PMRUs) and state drug controllers to catch violators.

“The system is only as strong as its enforcement,” warns Dr. Singh. “We still see instances where hospitals might bundle the ‘discounted’ price of a device with higher ‘procedure charges’ or ‘nursing fees’ to recoup the lost margin.”

Furthermore, the 10% annual increase allowance for non-scheduled devices can still outpace inflation, potentially straining the budgets of those with chronic conditions requiring long-term monitoring.

What This Means for You

For the health-conscious consumer, understanding these regulations is a tool for financial protection. When scheduling a surgery or purchasing a medical device:

• Ask for the Schedule-I Status: Inquire if the device (like a stent or knee implant) falls under the NPPA ceiling price.

• Verify the MRP: Check the packaging of glucometers or BP monitors; the price should not have jumped more than 10% in the last year.

• Demand Itemization: Ensure your hospital bill breaks down the specific cost of the hardware used in your body.

• Report Discrepancies: If you suspect overcharging, grievances can be lodged through the NPPA’s “Pharma Sahi Daam” app or via State Drug Controllers.

As the NPPA continues to monitor the market and purchase samples from the open market for testing, the message to the industry is clear: essential healthcare must remain accessible.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References and Sources

• Ministry of Chemicals and Fertilizers. (2026, March 17). Issue of high trade margins in essential medical devices. Press Information Bureau (PIB), Delhi.